Skip to main content
PharmaEssentia Corporation logo

PharmaEssentia Corporation — Investor Relations & Filings

Ticker · 6446 ISIN · TW0006446008 LEI · 54930001GNQLDIFASK68 TW Manufacturing
Open in API
Filings indexed 38 across all filing types
Latest filing 2026-05-22 Director's Dealing
Country TW Taiwan
Listing TW 6446

About PharmaEssentia Corporation

http://www.PharmaEssentia.com

PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.

Recent filings

Filing Released Lang Actions
115年5月21日內部人設質解質
Director's Dealing Classification · 90% confidence The document is a report from the public disclosure system showing share pledge (質權) changes by company directors (the chairman and a director) with details on pledge dates, number of shares pledged, pledgee, and filing dates. This falls under insider transactions by directors. Therefore, it matches the "Director’s Dealing" category.
2026-05-22 Chinese
公告更正本公司115年第一季合併財務報告附註 揭露內容
Report Publication Announcement Classification · 85% confidence The document is a notice from a listed company to announce a correction (“更正”) to its previously published Q1 consolidated financial report notes and that the corrected report has been re-uploaded to the disclosure website. It does not contain full financial statements but rather informs investors of the republishing of a corrected report. This fits the definition of a Report Publication Announcement (RPA).
2026-05-19 Chinese
115年05月法人說明會簡報 — 644620260514E001.pdf
Investor Presentation Classification · 10% confidence The document is a slide-based presentation (with forward-looking statements and slide numbers) providing a detailed overview of Q1’26 financial performance, strategy, product pipeline, market opportunity, and clinical updates to investors and analysts. This format and content align with an Investor Presentation rather than an actual report filing. Therefore, it is classified as an Investor Presentation (IP).
2026-05-14 English
115年05月法人說明會簡報 — 644620260514M001.pdf
Investor Presentation Classification · 96% confidence The document is a slide-based presentation containing forward‐looking statements, detailed Q1’26 financial highlights (revenue, net profit, EPS, margins), product pipeline updates, market analyses, clinical trial data, and strategic objectives. It is structured as an investor slide deck rather than an annual/quarterly report, press release, or regulatory filing. This matches the definition of an Investor Presentation (IP).
2026-05-14 English
115年05月法人說明會簡報
Regulatory Filings Classification · 75% confidence The document is a short regulatory notice from Taiwan’s public information site listing a company’s institutional investor presentation date, time, location, and links to slide deck PDFs. It does not include substantive financial data or the presentation content itself—only an announcement with attachments. This does not fit the detailed Investor Presentation category (which requires the presentation content) and is best classified as a general regulatory filing announcement.
2026-05-14 Chinese
115年第1季財務報告書 — 202601_6446_AI1.pdf
Interim / Quarterly Report Classification · 96% confidence The document is a consolidated financial report for the three‐month periods ended March 31 (Interim periods), including auditor’s review (EY), detailed balance sheet, income statement, cash flow statement, and extensive notes under IFRS 34 “Interim Financial Reporting.” It is not merely an announcement or summary but the full interim financial statements. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.